Department of Health & Social Care

NHS England

Medicine Supply Notification

MSN/2024/045

Naloxegol (Moventig®) 12.5mg and 25mg tablets

Tier 2 – medium impact*
Date of issue: 23/04/2024
Link: Medicines Supply Tool

Summary

- Naloxegol (Moventig®) 12.5mg tablets are out of stock until early August 2024.
- Naloxegol (Moventig®) 25mg tablets are out of stock until the end of April 2024.
- Naldemedine (Rizmoic®) 200 micrograms tablets remain available and can support increased demand.

Actions Required

Clinicians should not initiate new patients on naloxegol (Moventig®) tablets until the supply issues resolve.

Where patients have insufficient supply of either strength of naloxegol to last until the resupply date(s) consider:

- prescribing naldemedine (Rizmoic®) 200 microgram tablets; or
- when available, review if a 25mg dose of naloxegol may be appropriate for some patients; and
- for patients requiring a 12.5mg dose of naloxegol, for whom a trial of naldemedine has not proven to be as effective or tolerated, consider off-label halving of naloxegol (Moventig®) 25mg tablets, to deliver a 12.5mg dose. Ensure a tablet cutter is provided and patients (or their carers) are counselled on dosing and the use of a tablet cutter (see Supporting information).

Supporting Information

Naloxegol is a peripheral opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative(s). The recommended dose is 25mg once daily.

The starting dose for patients with moderate or severe renal insufficiency is 12.5mg daily. The dose can be increased to 25mg if 12.5mg is well tolerated by the patient. The 25mg tablets are film-coated and unscored; no data are available on halving them, and this manipulation would be considered off-label, although the product licence does allow for the tablets to be crushed to a powder and mixed in water for patients unable to swallow the tablet whole.

Naldemedine is another peripherally acting opioid receptor antagonist licensed for the same indication. The recommended dose is 200 micrograms daily. No dose adjustment is required in patients with renal impairment, but due to the limited therapeutic experience, patients with severe renal impairment should be clinically monitored when initiating therapy.

Both agents are NICE approved for use within their marketing authorisations.

*Classification of Tiers can be found at the following link:
https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/

Links to further information

SmPC naloxegol (Moventig®) tablets
SmPC naldemedine (Rizmoic®) tablets
BNF naloxegol
BNF naldemedine

Guidance on prescribing off-label medicines

Any decision to prescribe an off-label medicine must consider the relevant guidance and NHS Trust or local governance procedures. Please see the links below for further information:

- The supply of unlicensed medicinal products, Medicines and Healthcare products Regulatory Agency (MHRA)
- Professional Guidance for the Procurement and Supply of Specials, Royal Pharmaceutical Society
- Prescribing unlicensed medicines, General Medical Council (GMC),

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.